Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
- Conditions
- Ulcerative ColitisGastrointestinal DiseaseInflammatory Bowel Disease
- Registration Number
- NCT00073047
- Lead Sponsor
- Facet Biotech
- Brief Summary
The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis. This study is being conducted at up to 38 clinical research centers in the US, Canada, and Belgium, and is open to male and female patients 12 years and older. Participants in the study will have a number of visits to a research center over a five-month period. All study related care and medication is provided to qualified participants at no cost: this includes all visits, examinations, and laboratory work.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (34)
Clinical Research Associates
🇺🇸Hollywood, Florida, United States
Advanced Medical Research Institute
🇺🇸Anaheim, California, United States
Research Foundation of America
🇺🇸Los Angeles, California, United States
Western Gastroenterology Group
🇺🇸Los Angeles, California, United States
Cedar Sinai Medical Center
🇺🇸Los Angeles, California, United States
GVAMC
🇺🇸Gainesville, Florida, United States
Physician Office
🇺🇸Jacksonville, Florida, United States
Mount Sinai Medical Center
🇺🇸North Miami Beach, Florida, United States
Atlanta Gastroenterology Associates
🇺🇸Atlanta, Georgia, United States
The University of Chicago Hospital
🇺🇸Chicago, Illinois, United States
Scroll for more (24 remaining)Clinical Research Associates🇺🇸Hollywood, Florida, United States